Feigal EG - Search Results

1

The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Scheiner ZS, Talib S, Feigal EG. Scheiner ZS, et al. Among authors: feigal eg. J Biol Chem. 2014 Feb 21;289(8):4571-7. doi: 10.1074/jbc.R113.509588. Epub 2013 Dec 20. J Biol Chem. 2014. PMID: 24362036 Free PMC article. Review.

2

Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.

Andrews PW, Cavagnaro J, Deans R, Feigal E, Horowitz E, Keating A, Rao M, Turner M, Wilmut I, Yamanaka S. Andrews PW, et al. Nat Biotechnol. 2014 Aug;32(8):724-6. doi: 10.1038/nbt.2973. Nat Biotechnol. 2014. PMID: 25093882 No abstract available.

3

The Alpha Stem Cell Clinic: a model for evaluating and delivering stem cell-based therapies.

Trounson A, DeWitt ND, Feigal EG. Trounson A, et al. Among authors: feigal eg. Stem Cells Transl Med. 2012 Jan;1(1):9-14. doi: 10.5966/sctm.2011-0027. Stem Cells Transl Med. 2012. PMID: 23197634 Free PMC article.

4

Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Canet-Aviles R, Lomax GP, Feigal EG, Priest C. Canet-Aviles R, et al. Among authors: feigal eg. Stem Cells Transl Med. 2014 Sep;3(9):979-91. doi: 10.5966/sctm.2014-0146. Epub 2014 Aug 22. Stem Cells Transl Med. 2014. PMID: 25150264 Free PMC article.

5

The proceedings of the California Stem Cell Agency.

Feigal EG, DeWitt ND. Feigal EG, et al. Stem Cells Transl Med. 2014 Jun;3(6):671-2. doi: 10.5966/sctm.2014-0068. Epub 2014 Apr 25. Stem Cells Transl Med. 2014. PMID: 24771394 Free PMC article.

6

Proceedings: international regulatory considerations on development pathways for cell therapies.

Feigal EG, Tsokas K, Viswanathan S, Zhang J, Priest C, Pearce J, Mount N. Feigal EG, et al. Stem Cells Transl Med. 2014 Aug;3(8):879-87. doi: 10.5966/sctm.2014-0122. Epub 2014 Jul 18. Stem Cells Transl Med. 2014. PMID: 25038248 Free PMC article.

7

Perspective: communications with the Food and Drug Administration on the development pathway for a cell-based therapy: why, what, when, and how?

Feigal EG, Tsokas K, Zhang J, Cromer MV, Whittlesey KJ, Werner MJ. Feigal EG, et al. Stem Cells Transl Med. 2012 Nov;1(11):825-32. doi: 10.5966/sctm.2012-0104. Epub 2012 Oct 17. Stem Cells Transl Med. 2012. PMID: 23197694 Free PMC article.

8

How California Institute for Regenerative Medicine research programs support science and regulatory policy.

Lomax GP, DeWitt ND, Millan MT, Feigal EG. Lomax GP, et al. Among authors: feigal eg. Stem Cells Transl Med. 2014 Jun;3(6):673-4. doi: 10.5966/sctm.2014-0069. Epub 2014 Apr 25. Stem Cells Transl Med. 2014. PMID: 24771395 Free PMC article.

9

At the end of the beginning: immunotherapies as living drugs.

Feigal EG, DeWitt ND, Cantilena C, Peck C, Stroncek D. Feigal EG, et al. Nat Immunol. 2019 Aug;20(8):955-962. doi: 10.1038/s41590-019-0452-8. Nat Immunol. 2019. PMID: 31308544 No abstract available.

10

Developing cellular therapies for retinal degenerative diseases.

Bharti K, Rao M, Hull SC, Stroncek D, Brooks BP, Feigal E, van Meurs JC, Huang CA, Miller SS. Bharti K, et al. Invest Ophthalmol Vis Sci. 2014 Feb 26;55(2):1191-202. doi: 10.1167/iovs.13-13481. Invest Ophthalmol Vis Sci. 2014. PMID: 24573369 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters